



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/820,215	04/07/2004	Eric J. Benjamin	AM101252	7245		
25291	7590	03/19/2010	EXAMINER			
WYETH LLC			COLEMAN, BRENDA LIBBY			
PATENT LAW GROUP			ART UNIT			
5 GIRALDA FARMS			PAPER NUMBER			
MADISON, NJ 07940			1624			
NOTIFICATION DATE		DELIVERY MODE				
03/19/2010		ELECTRONIC				

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

-IPGSMadisonDocketing@pfizer.com

RECORD OF ORAL HEARING
UNITED STATES PATENT AND TRADEMARK OFFICE

**BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES**

Ex parte ERIC J. BENJAMIN, REINHARDT B. BAUDY and
MICHAEL R. BRANDT

Appeal 2009-008378
Application 10/820,215
Group Art Unit 1600

Oral Hearing Held: February 2, 2010

Before TONI R. SCHEINER, DONALD E. ADAMS, and
LORA M. GREEN, *Administrative Patent Judges*

ON BEHALF OF THE APPELLANTS:

MICHAEL J. MORAN, ESQ.
JOEL SILVER, Agent
Wyeth LLC
5 Giralda Farms
Madison, NJ 07940

1 THE CLERK: Good morning. Calendar number 7, appeal
2 number 2009-008378, Mr. Silver.

3 JUDGE SCHEINER: Thank you. Good morning.

4 MR. SILVER: Good morning.

5 JUDGE SCHEINER: Okay. And you are Mr. Moran?

6 MR. MORAN: I am. Do I –

7 JUDGE SCHEINER: Okay. Yes, wherever you like. Here is
8 the -- we have two names here, for the record. Can we move that out of your
9 way for you?

10 MR. MORAN: I'm fine.

11 JUDGE SCHEINER: Okay. Good morning.

12 MR. SILVER: Good morning. I am Joel Silver. This is
13 Michael Moran, representing Wyeth.

14 JUDGE SCHEINER: Okay.

15 MR. SILVER: I would like to thank the Board for taking --
16 giving us the opportunity to present this case.

17 So, kind of just to give you an introduction on the case, a brief
18 layout, the compound, the phosphonic, a phosphonic acid compound, is a
19 known NMDA antagonist. However, what the invention is directed to is a
20 novel intra nasal administration method.

21 So, what we have shown is that the compound is more
22 efficacious, tenfold more so than the oral administration method, and
23 equivalent in -- to the IP, or intraperitoneal, administration method.

24 The claims -- currently Claims 1 through 9 and Claims 26
25 through 41 -- are rejected under 112, as well as Claims 10 through 23 and 42
26 through 56. There is also a 102 rejection. I would like to start with the 112
27 rejection.

1 JUDGE SCHEINER: Okay.

2 MR. SILVER: The Claims 1 through 9 and 26 through 41 are
3 pharmaceutical composition claims. They are rejected as being directed to
4 pharmaceutical compositions for treatment of any and all diseases and/or
5 conditions associated with amino acid receptor activity. But the claims do
6 not recite a specific indication.

7 So, it appears the Examiner is reading a method of treatment
8 into the pharmaceutical composition claim –

9 JUDGE GREEN: But didn't the Examiner make one ground o f
10 rejection over all the claims, Claims 1 through 56?

11 MR. SILVER: Yes. But –

12 JUDGE GREEN: Now, did you argue the composition claims
13 separately from the method claims in your Appeal Brief? Because I would
14 like to see where you did that.

15 MR. SILVER: The -- in the Reply Brief?

16 JUDGE GREEN: No, the Appeal Brief.

17 (Pause.)

18 MR. SILVER: So, in the -- on page 12, the pharmaceutical
19 composition claims meet the enablement requirements under 112. Do you
20 have that?

21 JUDGE GREEN: Right.

22 MR. SILVER: First paragraph, "Appellants have described
23 detail to enable a skilled person to use the intra nasal composition" --

24 JUDGE GREEN: But you do not even point out what claims
25 are, the composition claims, right?

26 MR. SILVER: In the Appeal Brief?

27 JUDGE GREEN: Or in the Reply Brief.

1 MR. SILVER: In the Reply Brief they are pointed out on –
2 (Pause.)

3 MR. SILVER: The claims aren't split out –

4 JUDGE GREEN: So, I mean, you have not said anywhere that
5 the claims do not stand all together. You do not tell me what groups are --
6 what claims are in the two different groups. How am I supposed -- you want
7 me to treat this as separate -- the compositions separately from the methods?

8 MR. SILVER: I would like to consider the different standards
9 of the pharmaceutical composition claims –

10 JUDGE GREEN: I understand that there are different
11 standards. And I have no issues with that.

12 MR. SILVER: Okay.

13 JUDGE GREEN: My issue is you have just kind of done this
14 gloss, saying that -- the composition and then the method, but you have not
15 come out, pulled out claims, said whey they are separately patentable, or
16 anything else.

17 The only thing your heading says is Claims 1 through 56 are
18 enabled. To me, that means that you are arguing all the claims together. So,
19 I am asking you why I should consider them separately.

20 MR. SILVER: I think I agree that they are not split out with
21 respect to the -- the arguments don't specify which claims in our
22 pharmaceutical composition versus method. I think the arguments are split
23 with respect to the treatments in the pharmaceutical composition.

24 If I can then direct to the method of treatment arguments, as
25 well, the -- as I said, the compound isn't a known NMDA antagonist. And
26 basically, the invention sets forth a more efficacious administration method.

1 And the NMDA target is a well-known target for treating a number of
2 different diseases.

3 JUDGE GREEN: But -- it is a well-known target, but it -- I
4 mean the art that you have brought in is saying how hard this is to target,
5 therapeutically. Like, one of the references -- I think it is the Bergink
6 reference -- says that NMDA receptor antagonism is not a valid therapeutic
7 approach for the treatment of anxiety disorders. And that is the paragraph
8 bridging 180 to 181.

9 The Wood reference at page 231, "NMDA receptor modulators
10 will probably never be effective treatments for stroke," and it seems to be
11 due -- because these things are involved in so many things.

12 MR. SILVER: Right.

13 JUDGE GREEN: How do you target this without getting this,
14 and get all these other CNS side effects and everything?

15 And I do not think your specifications addressed any of that.
16 And your specification says you were going to treat all of this. So I am
17 really having a hard time with the methods, given the art that you provided
18 me, to say, "Hey, these are enabled."

19 MR. SILVER: Okay. Yes, so the treatment methods -- this
20 does have -- the CNS or the NMDA receptor is targeting a number of
21 different disorders, and I think the Wood reference does point that out.

22 JUDGE GREEN: But they are saying that it is so -- it's
23 everywhere that this is involved in, that you cannot -- it's very hard to target
24 the condition you want to target, having all these other side effects.

25 MR. SILVER: And I think that has been a complication of
26 some of the compounds.

1 JUDGE GREEN: But you have not shown me that your
2 compound -- or any evidence that your compound does not hit any of these,
3 have any of these other side effects. And you want to treat stroke, you want
4 to treat schizophrenia, you want to treat anxiety, you want to -- I mean you
5 want to treat basically anything that an NMDA receptor is involved with.

6 So, I am having a hard time seeing how your method claims are
7 enabled, given that you have one model, and that is the tail model with the
8 mouse. And even your art that you brought in says there are issues with this
9 model, because they are not sure if it is due to the activity of the compound,
10 or something else that is going on. So –

11 MR. SILVER: And I think that side effects are a concern that --
12 and when these references are referring to issues with compounds going
13 forward with the FDA, they will link to the first stage of the FDA trials,
14 which is the safety studies. I think, for patentability, the standard is not the
15 same as under the FDA for regulatory –

16 JUDGE GREEN: I understand that. But you have to have an
17 enablement that one of ordinary skill in the art will believe. And what we
18 have is what -- you have to have an art accepted model and an art accepted
19 correlation. From what I gather from the art that you submitted, there does
20 not seem to be any art accepted model or art accepted correlation. So that is
21 where the disconnect is.

22 I agree, we do not have to follow the FDA standards. But we
23 do have something that one of ordinary skill in the art would understand may
24 have a correlation to clinical efficacy. And I do not see that, especially
25 given the references that you cited to me to say, "These are enabled." All
26 these references are saying this is never going to work here, this is never

1 going to work here. The models that we do have do not seem to correlate
2 very well.

3 And you have not even focused on one particular disease, or
4 one particular -- that this may actually work very well in. You have just
5 thrown them all in there. So, how do I pick and choose? I cannot –

6 MR. SILVER: Well, I think with respect to the hypersensitivity
7 model does correlate to -- it's basically a stimulant, a pain –

8 JUDGE GREEN: But we are not limited to pain. I mean you
9 are claiming everything in your method claims.

10 MR. SILVER: Well, just with respect to Claim 21 –

11 JUDGE GREEN: But you have not argued those separately.
12 Then we are back to that again. I mean at best, you may have argued the
13 compositions differently from the methods. And I am not sure that you have
14 done that. I am going to have to go back and relook.

15 MR. SILVER: Okay.

16 JUDGE GREEN: Under our rules, you have not. Under our
17 rules, you are supposed to have separate headings, and list the claims, and
18 everything else. You have not done any of that.

19 But even then, at best, those might be the two groups you get.
20 And I am not even saying that I can pull those two groups out. But the
21 method claims, I am not going to start pulling the pain method from the
22 anxiety from the schizophrenia, from everything else, because you haven't
23 argued any of those separately. And you haven't pointed me out to what
24 claims that those particular disorders go to, or anything else.

25 So, there is a little bit of a burden here on your part to tell me
26 what claims we are talking about, and why it should be separately
27 patentable, given the rejection.

1 MR. SILVER: I specifically identified the –

2 JUDGE GREEN: Yes, and if you look at our rules, that is what
3 it says to do.

4 MR. SILVER: Sure, right.

5 JUDGE GREEN: To have separate headings –

6 MR. SILVER: Yes.

7 JUDGE GREEN: -- with different claim numbers, and
8 everything else. So –

9 MR. SILVER: Should we move on to the 102 –

10 JUDGE GREEN: Yes, please.

11 MR. SILVER: So, the current 102 rejection is over Lynn.
12 Lynn is directed to rapamycin administration, in conjunction with other
13 agents. Lynn is not directed to an intra nasal administration.

14 JUDGE GREEN: Well, Lynn does say you can do -- use an
15 intra nasal administration.

16 MR. SILVER: Yes, yes, absolutely. So Lynn does disclose
17 that you can administer rapamycin intranasally. The issue is that Lynn
18 doesn't disclose what we are claiming, which is the intra nasal
19 administration for phosphonic acid.

20 JUDGE GREEN: But if we look at Claim 1, which is drawn to
21 the composition -- correct?

22 MR. SILVER: Yes.

23 JUDGE GREEN: Our Claim 1?

24 JUDGE GREEN: Wait, I -- yes. Pharmaceutical composition
25 for intra nasal administration, yes. So it is a composition?

26 MR. SILVER: Mm-hmm.

1 JUDGE GREEN: Okay. And in your specification, you define
2 intra nasal, what is required for it, very generally. Like, "All you really need
3 is a lipid carrier, and then maybe some other excipients or anything else,"
4 but really, you do not require much for intra nasal administration in your --
5 for the composition itself.

6 MR. SILVER: Yes, an intra nasal –

7 JUDGE GREEN: But to me, intra nasal could read on this
8 compound and saline, correct?

9 MR. SILVER: Correct.

10 JUDGE GREEN: So -- and then Lynn teaches the rapamycin --
11 if you look at lines -- let me see, I think it is 23, 24, and 25 on page 3 of
12 Lynn. "This invention provides a pharmaceutical composition comprising
13 rapamycin and an NMDA antagonist in a pharmaceutically acceptable
14 carrier," which could be saline. And your comprising language does not
15 exclude the rapamycin.

16 MR. SILVER: Well, with the -- where Lynn does disclose the
17 intranasally –

18 JUDGE GREEN: But -- I understand that, but your Claim 1 is
19 a composition claim. It does not require -- all it has to be is suitable for intra
20 nasal administration, which could be a saline solution.

21 MR. SILVER: Right.

22 JUDGE GREEN: So, when we look at the composition, here
23 we have a composition comprising one of your compounds that -- of your
24 claim compounds, rapamycin, and a pharmaceutically acceptable carrier,
25 which they teach could be -- you know, I think they specifically teach one
26 that is water and a buffer.

27 MR. SILVER: Well, it –

1 JUDGE GREEN: So they say the pharmaceutical carrier may
2 be a liquid, such as water, Tween 80, and phosphocel or phosphogel PG-50.
3 That is at page six, I think -- the line bridging pages six and seven.

4 Well, they call it an oral formulation. Why wouldn't that be
5 suitable for intra nasal administration, given the broad definition of that kind
6 of composition that you have in your specification?

7 MR. SILVER: Well, again, that is a carrier for rapamycin.

8 JUDGE GREEN: But they teach -- they specifically teach -- a
9 composition comprising rapamycin and NMDA antagonists in a
10 pharmaceutically acceptable carrier, and they are saying this is a
11 pharmaceutically acceptable carrier.

12 MR. SILVER: Right. The -- well, I guess what I was saying is
13 the specific -- when you take the two elements and you combine them into
14 that, the NMDA -- our specific compound is listed in a list of different agents
15 that can be potentially combined.

16 JUDGE GREEN: But it is not a huge list, and it is specifically
17 listed. I mean we have the species listed; we do not have a genus listed.

18 MR. SILVER: Right.

19 JUDGE GREEN: I mean it may anticipate more than your
20 particular composition, with your particular compound, but I mean, it does --
21 it is not a huge list of additional compounds that could be put in with the
22 rapamycin. That would be beyond the level of skill of the ordinary artisan to
23 envision all of these in a composition with rapamycin. And isn't that the test
24 for 102?

25 MR. SILVER: Right. The test for 102 is that all of the
26 elements are identically disclosed in the reference. I think that, specifically

1 with respect to this pharmaceutical composition, that the specific compound
2 isn't particularly culled out. And that would require picking from this list.

3 JUDGE GREEN: So we have a list of seven NMDA
4 antagonists.

5 (Pause.)

6 JUDGE ADAMS: Anything else?

7 MR. MORAN: Could we have one minute?

8 JUDGE SCHEINER: Sure.

9 (Pause.)

10 MR. SILVER: Yes, I think that was it.

11 JUDGE SCHEINER: Okay, thank you.

12 MR. SILVER: Thank you.

13 Whereupon, at 10:05 a.m., the proceedings were concluded.

14 * * * *

15

16

17

18

19

20